Form 8-K - Current report:
SEC Accession No. 0001628280-22-026779
Filing Date
2022-10-21
Accepted
2022-10-21 06:12:35
Documents
12
Period of Report
2022-10-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K auph-20221017.htm   iXBRL 8-K 36879
  Complete submission text file 0001628280-22-026779.txt   172115

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20221017.xsd EX-101.SCH 1930
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20221017_lab.xml EX-101.LAB 23832
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20221017_pre.xml EX-101.PRE 12530
6 EXTRACTED XBRL INSTANCE DOCUMENT auph-20221017_htm.xml XML 10828
Mailing Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8
Business Address #1203-4464 MARKHAM STREET VICTORIA BC A1 V8Z 7X8 250-708-4272
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 000000000 | State of Incorp.: A0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36421 | Film No.: 221322152
SIC: 2834 Pharmaceutical Preparations